HARMONIZE was a phase 3 , multicenter , randomized , double-blind , placebo-controlled trial evaluating zirconium cyclosilicate in outpatients with hyperkalemia ( serum potassium 5.1 mEq/L ) recruited from 44 sites in the United States , Australia , and South Africa ( March-August 2014 ) .